Because of the prognostic usefulness of CEA, the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) recommended CEA level to be considered as a golden follow-up standard after CRC therapy [34, 35]. Here, CEACAM5 is linked to colorectal carcinoma.